You just read:

FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition

News provided by

CSL Behring

14 Feb, 2017, 09:30 ET